24
Participants
Start Date
May 23, 2023
Primary Completion Date
April 30, 2025
Study Completion Date
April 30, 2025
zetomipzomib
Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
placebo
Subcutaneous injection of placebo
zetomipzomib in open-label extension
Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
New York University Langone Health/Grossman School of Medicine, New York
Northwell Health Center for Liver Disease and Transplantation, Manhasset
University of Pennsylvania, Philadelphia
Virginia Commonwealth University, Richmond
Duke University Medical Center, Durham
Mayo Clinic Florida, Jacksonville
University of Miami, Miami
University Hospitals Cleveland Medical Center, Cleveland
Indiana University, Indianapolis
University of Michigan Medical Center, Ann Arbor
Northwestern University, Chicago
Rush University, Chicago
Washington University School of Medicine, St Louis
Ochsner Clinic Foundation, New Orleans
University of Colorado, Aurora
Mayo Clinic Arizona, Phoenix
Keck School of Medicine of USC, Los Angeles
University of California, Los Angeles, Los Angeles
Stanford Medicine, Redwood City
California Pacific Medical Center, San Francisco
University of California, San Francisco, San Francisco
Yale University, New Haven
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Lead Sponsor
Kezar Life Sciences, Inc.
INDUSTRY